Saxenda Cost vs. Alternatives: What You Actually Pay and What You Get
HealthRX.com
Saxenda's price depends heavily on insurance and where you buy
Key numbers
- 4%Minimum weight loss by week 16 below which the label says to stop SaxendaSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 39.3%Adults on Saxenda reporting nausea in placebo-controlled trials, versus 13.8% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 9.8%Share of adults on Saxenda who stopped treatment due to adverse reactionsSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 3 mgRecommended adult daily dose of Saxenda, a once-daily injectionSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
From the public record
Medicare Part D spending on liraglutide
Medicare Part D spending on liraglutide products was $329.0M in 2024 across 351,843 claims, compared with $1.32B in 2023 (-75.1%). Average spending per claim was $935, before rebates.
| Measure | Value | Note |
|---|---|---|
| Total spending, 2024 | $329.0M | |
| Total spending, 2023 | $1.32B | |
| Change in spending, 2023 to 2024 | -75.1% | |
| Claims (prescription fills), 2024 | 351,843 | |
| Average spending per claim, 2024 | $935 | |
| Victoza 3-Pak: spending, 2024 | $203.1M | 181,068 claims |
| Victoza 2-Pak: spending, 2024 | $77.8M | 108,521 claims |
| Liraglutide: spending, 2024 | $48.1M | 62,254 claims |
How this was calculated
Summed total spending and claims over every brand and generic row with this generic name in the CMS file, using the Overall manufacturer rows. Combination products excluded. Average per claim is spending divided by claims.
Every single-ingredient liraglutide product in Part D (Victoza 3-Pak, Victoza 2-Pak, Liraglutide), 2024. Not limited to Saxenda.
Gross drug cost before manufacturer rebates, so net cost is lower. Part D excludes some uses by law (for example erectile dysfunction, weight loss and hair growth), so claims reflect covered uses only. Compounded products are not included.
From the public record
Medicaid prescriptions for Saxenda by state
State Medicaid programmes paid for 28,807 Saxenda prescriptions in 2025, with $34.2M reimbursed before rebates. California reported the most (10,868), followed by Virginia (8,783) and Michigan (2,442); 15 states and territories reported any.
| Measure | Value | Note |
|---|---|---|
| Prescriptions paid by Medicaid, 2025 | 28,807 | |
| Total reimbursed before rebates, 2025 | $34.2M | |
| States and territories reporting | 15 | with at least one count CMS did not suppress |
| California | 10,868 prescriptions | $13.2M reimbursed |
| Virginia | 8,783 prescriptions | $10.2M reimbursed |
| Michigan | 2,442 prescriptions | $3.0M reimbursed |
| Minnesota | 2,091 prescriptions | $2.4M reimbursed |
| Pennsylvania | 1,542 prescriptions | $2.0M reimbursed |
How this was calculated
Matched each Medicaid product code to the FDA NDC Directory by labeler and product code, kept finished single-ingredient products, then summed prescriptions and reimbursement by state. National roll-up and suppressed rows dropped.
Saxenda only (brand-name liraglutide), fee-for-service and managed care, 2025
Counts under 11 are suppressed by CMS and left out, so totals are a floor. Amounts are before rebates. Differences between states reflect programme size and coverage rules. Compounded products are not included.
From the public record
Pharmacy acquisition cost (NADAC) for Saxenda
Retail pharmacies paid an average of $87.04 per mL for SAXENDA 18 MG/3 ML PEN as of 2026-11-11, compared with $86.99 twelve months earlier (+0.1%). This is a pharmacy purchase cost, not a patient price.
| Measure | Value |
|---|---|
| SAXENDA 18 MG/3 ML PEN, now | $87.04 per mL |
| SAXENDA 18 MG/3 ML PEN, 12 months earlier | $86.99 per mL |
| Change over 12 months | +0.1% |
How this was calculated
Matched NADAC product codes to the FDA NDC Directory, kept finished single-ingredient products, and listed the product descriptions with the most package codes. The earlier price is the same package code in the file one year before.
Saxenda (brand-name liraglutide) in the weekly NADAC file of 2026-11-11, compared with the file of 2025-11-12
NADAC is the average invoice price retail pharmacies pay, from a voluntary survey. It leaves out rebates, dispensing fees and markups, and it is not what a patient or insurer pays. Compounded products are not surveyed.
At a glance
- Drug / Saxenda (liraglutide 3 mg), once-daily subcutaneous injection [3]
- Approved for / Weight management with a reduced-calorie diet and more physical activity: adults with obesity, adults with overweight plus a weight-related condition, and ages 12 and older above 60 kg with obesity [3]
- Main trial / SCALE Obesity and Prediabetes, 3,731 adults, 56 weeks: 8.4 kg versus 2.8 kg mean loss [1]
- Responders / 63.2% lost at least 5% of body weight versus 27.1% on placebo [1]
- Stopping rule / The label says to discontinue if less than 4% of baseline weight is lost by week 16 [3]
- Generic / FDA-approved generic liraglutide exists [2]
- Compounding / FDA proposed on 2026-04-30 to exclude liraglutide from the bulk substances list for outsourcing facilities [4]
What the main trial measured
SCALE Obesity and Prediabetes enrolled 3,731 adults without type 2 diabetes, with a BMI of at least 30, or at least 27 plus dyslipidemia or hypertension. They were assigned 2:1 to liraglutide 3.0 mg (2,487 people) or placebo (1,244), both with lifestyle counseling. At week 56 the liraglutide group had lost a mean 8.4 kg versus 2.8 kg, a difference of 5.6 kg (95% CI -6.0 to -5.1; P<0.001) [1]. At least 5% of body weight was lost by 63.2% versus 27.1% [1].
The 16-week checkpoint
The label starts at 0.6 mg daily and raises the dose weekly to 3 mg by week 5, the recommended adult dose [3]. The label says to check weight at week 16 and to discontinue if at least 4% of baseline body weight has not been lost, since continued treatment is unlikely to produce clinically meaningful weight loss [3]. The label also says not to combine Saxenda with another liraglutide-containing product or any other GLP-1 receptor agonist [3].
What you get in side effects
In 5 placebo-controlled adult trials (3,384 on Saxenda, 1,941 on placebo, up to 56 weeks), nausea occurred in 39.3% versus 13.8%, diarrhea in 20.9% versus 9.9%, constipation in 19.4% versus 8.5% and vomiting in 15.7% versus 3.9% [3]. Adverse reactions led 9.8% versus 4.3% to stop treatment, most often for nausea (2.9% versus 0.2%) [3].
Generic and compounded liraglutide
Generic liraglutide is FDA-approved [2]. Generic products that reference Saxenda carry the weight-management label, among them Teva (ANDA 214568), Biocon (ANDA 217063) and Cipla (ANDA 217234); those that reference Victoza carry the type 2 diabetes label instead, including Hikma (ANDA 215503, approved 2024-12-23), Lupin, Meitheal/NorthStar and a Teva authorized generic [2].
On 2026-04-30 FDA proposed to exclude semaglutide, tirzepatide and liraglutide from the bulk substances list that outsourcing facilities may compound with, finding no clinical need; comments ran to 2026-06-29 and no final decision was found [4]. FDA states compounded drugs are not FDA approved [4].
What people on Reddit report
Accounts from people paying for liraglutide pens, with or without insurance, in the US, Canada, Israel, New Zealand and other countries.
I'm in Arizona with employee sponsored insurance and my OOP is $25 through Caremark.Read the source discussion
My insurance covers 80%. Five pens costs me around a little bit more than $500 CAD and i pay a bit more around $100 CAD and that's the cheapest I can get. Maybe get it from Canada if that's possible?Read the source discussion
Questions worth asking
Frequently asked questions
Is there a generic version of Saxenda?
Can compounded liraglutide replace Saxenda?
How much weight do people lose on Saxenda?
Is Saxenda injected daily or weekly?
Can Saxenda be combined with another GLP-1 drug?
References
Show all 6 referencesHide references
- Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22.
- U.S. Food and Drug Administration.
- U.S. National Library of Medicine, DailyMed. Saxenda injection (liraglutide) prescribing information. Saxenda injection (liraglutide) label
- FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on Bulks List | FDA.
- Reddit participants. [deleted by user] (r/liraglutide). Accessed 2026-11-11.
- Reddit participants. [deleted by user] (r/liraglutide). Accessed 2026-11-11.